Transition Therapeutics (Transition Therapeutics) EV-to-EBIT : -2.93 (As of May. 06, 2024)

Transition Therapeutics EV-to-EBIT Chart

Transition Therapeutics Annual Data
	Trend	Jun06	Jun07	Jun08	Jun09	Jun10	Jun11	Jun12	Jun13	Jun14	Jun15
EV-to-EBIT		Get a 7-Day Free Trial					-9.70	-2.91	-60.89	-8.89	-1.07

Transition Therapeutics Quarterly Data
	Jun11	Sep11	Dec11	Mar12	Jun12	Sep12	Dec12	Mar13	Jun13	Sep13	Dec13	Mar14	Jun14	Sep14	Dec14	Mar15	Jun15	Sep15	Dec15	Mar16
EV-to-EBIT	Get a 7-Day Free Trial															-5.40	-1.07	-1.32	-2.55	-1.50

Competitive Comparison of Transition Therapeutics's EV-to-EBIT

For the Biotechnology subindustry, Transition Therapeutics's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Transition Therapeutics's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Transition Therapeutics's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Transition Therapeutics's EV-to-EBIT falls into.

Transition Therapeutics EV-to-EBIT Calculation

Transition Therapeutics's EV-to-EBIT for today is calculated as:

Transition Therapeutics's current Enterprise Value is $59.47 Mil.
Transition Therapeutics's EBIT for the trailing twelve months (TTM) ended in Mar. 2016 adds up the quarterly data reported by the company within the most recent 12 months, which was $-20.29 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Transition Therapeutics  (NAS:TTHI) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Transition Therapeutics's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2016 is calculated as:

Transition Therapeutics's Enterprise Value for the quarter that ended in Mar. 2016 was $31.04 Mil.
Transition Therapeutics's EBIT for the trailing twelve months (TTM) ended in Mar. 2016 adds up the quarterly data reported by the company within the most recent 12 months, which was $-20.29 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Transition Therapeutics EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Transition Therapeutics's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Transition Therapeutics (Transition Therapeutics) Business Description